Compare NAMS & GPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAMS | GPGI |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | Netherlands | United States |
| Employees | 100 | 977 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.4B |
| IPO Year | N/A | N/A |
| Metric | NAMS | GPGI |
|---|---|---|
| Price | $32.24 | $15.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $46.75 | N/A |
| AVG Volume (30 Days) | 977.5K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.07% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.96 | $768.10 |
| Revenue Next Year | $540.65 | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.53 | $11.22 |
| 52 Week High | $42.21 | $25.66 |
| Indicator | NAMS | GPGI |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 54.25 |
| Support Level | $29.23 | $11.30 |
| Resistance Level | $37.29 | $17.50 |
| Average True Range (ATR) | 1.83 | 0.84 |
| MACD | -0.12 | -0.15 |
| Stochastic Oscillator | 13.60 | 31.06 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.